<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03448159</url>
  </required_header>
  <id_info>
    <org_study_id>17-5134.0</org_study_id>
    <nct_id>NCT03448159</nct_id>
  </id_info>
  <brief_title>Fluoxetine Opens Window to Improve Motor Recovery After Stroke</brief_title>
  <acronym>FLOW</acronym>
  <official_title>FLOW Trial: Fluoxetine to Open the Critical Period Time Window to Improve Motor Recovery After Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalhousie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parkwood Hospital, London, Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Waterloo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial University of Newfoundland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Applied Health Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brain Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heart and Stroke Foundation Canadian Partnership for Stroke Recovery</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The FLOW trial is a randomized placebo-controlled trial analyzing the effect of coupling an
      anti-depressant, fluoxetine (Prozac), and exercise to improve motor recovery following a
      stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FLOW Trial is a randomized, placebo-controlled, blinded phase II trial evaluating the
      efficacy of coupling antidepressant therapy (e.g., selective serotonin reuptake inhibitor -
      fluoxetine) with exercise rehabilitation across multiple Canadian sites in 176 stroke
      patients. 88 patients will be enrolled in each arm of the study. Both groups will receive an
      exercise program in addition to standard of care rehabilitation, but only one group (the
      intervention group) will receive the active drug fluoxetine.

      Study participants will be evaluated at baseline, post-exercise program and 6-months
      post-exercise program. While enrolled in the study, participants will be required to take
      part in a 12 week, 3 times per week exercise program. Evaluators and patients will be blind
      to the treatment administered. The trial is constructed with randomization to remove
      selection and allocation biases and to ensure greater validity in observed differences in the
      outcome measures. The Applied Health Research Centre (AHRC) in Toronto will act as the
      coordinating and analysis center.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm 1: Intervention group (will receive the trial drug, fluoxetine, as well as an exercise intervention) Arm 2: Placebo group (will receive a placebo as well as an exercise intervention</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fugl-Meyer Lower Extremity Score</measure>
    <time_frame>Following completion of the 12-week exercise intervention</time_frame>
    <description>Fugl-Meyer Lower Extremity Assessment assesses motor and sensorimotor impairment in the lower extremities. Total score is between 0 and 34. Sub-scales include: proximal (0-18), knee/ankle (0-10) and coordination/speed (0-6). Higher scores indicate better performance. Sub-scale scores are summed to calculate total score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk Test / 10 Meter Walk Test</measure>
    <time_frame>Following completion of the 12-week exercise intervention and 6-months post-exercise intervention</time_frame>
    <description>Physical Measurement - Ambulatory Function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee Strength</measure>
    <time_frame>Following completion of the 12-week exercise intervention and 6-months post-exercise intervention</time_frame>
    <description>Physical Measurement- Lower Limb Strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Berg Balance Assessment</measure>
    <time_frame>Following completion of the 12-week exercise intervention and 6-months post-exercise intervention</time_frame>
    <description>Physical Measurement - Balance Function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip Strength</measure>
    <time_frame>Following completion of the 12-week exercise intervention and 6-months post-exercise intervention</time_frame>
    <description>Physical Measurement - Grip Strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist-to-Hip Ratio</measure>
    <time_frame>Following completion of the 12-week exercise intervention and 6-months post-exercise intervention</time_frame>
    <description>Physical Measurement - Health Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>Following completion of the 12-week exercise intervention and 6-months post-exercise intervention</time_frame>
    <description>Physical Measurement - Health Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke Impact Scale</measure>
    <time_frame>Following completion of the 12-week exercise intervention and 6-months post-exercise intervention</time_frame>
    <description>Stroke-specific, self-report, health status measure. Assesses multiple domains on a 5-point Likert scale. Domains include: strength (4-20), hand function (5-25), activities of daily living/instrumental activities of daily living (10-50), mobility (9-45), communication (7-35), emotion (9-45), memory and thinking (7-35), and participation (8-40). An extra question asks that the patient rate on a scale from 0 - 100 how much they feel that he/she has recovered from his/her stroke. The 4 physical domains (strength, hand function, mobility and activities of daily living) can be summed together to create a single, physical dimension score (28-140) while all other domains should remain separate. Higher scores indicate better function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fugl-Meyer Lower Extremity Score</measure>
    <time_frame>6-months post-exercise intervention</time_frame>
    <description>Impairment Measurement (see description above)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fugl-Meyer Upper Extremity Score</measure>
    <time_frame>Following completion of the 12-week exercise intervention and 6-months post-exercise intervention</time_frame>
    <description>Fugl-Meyer Upper Extremity Assessment assesses motor and sensorimotor impairment in the upper extremities. There is no total score for this measure. Sub-scales include: upper extremity (0-36), wrist (0-10), hand (0-14), coordination/speed (0-6) (which can be combined to form a total motor function score out of 66), and sensation (0-4). Higher scores indicate better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire (PHQ)-9</measure>
    <time_frame>Following completion of the 12-week exercise intervention and 6-months post-exercise intervention</time_frame>
    <description>Depression Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simple and Choice Reaction Time Test</measure>
    <time_frame>Following completion of the 12-week exercise intervention and 6-months post-exercise intervention</time_frame>
    <description>Cognitive Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trail Making Test - A &amp; B</measure>
    <time_frame>Following completion of the 12-week exercise intervention and 6-months post-exercise intervention</time_frame>
    <description>Cognitive Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (including 5 word recall and clock test)</measure>
    <time_frame>Following completion of the 12-week exercise intervention and 6-months post-exercise intervention</time_frame>
    <description>Cognitive Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Draws</measure>
    <time_frame>Following completion of the 12-week exercise intervention and 6-months post-exercise intervention</time_frame>
    <description>Biological Biomarker</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Stroke</condition>
  <condition>Cerebrovascular Accident</condition>
  <condition>Cerebral Infarction</condition>
  <condition>Brain Infarction</condition>
  <condition>Brain Ischemia</condition>
  <condition>Cerebrovascular Disorders</condition>
  <condition>Brain Diseases</condition>
  <condition>Central Nervous System Diseases</condition>
  <condition>Nervous System Diseases</condition>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>Fluoxetine Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluoxetine (Prozac) will be administered to this group. A ramp up period of 3-5 weeks will take place where the patient takes 10mg of Prozac per day. After that, the participant will take the regular dose of 20mg for the duration of the exercise intervention (12 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An over-encapsulated placebo, or &quot;sugar pill&quot; (so it appears identical to the trial drug) will be administered to this group. During the 3-5 week ramp up period for the experimental group, these participants will take a placebo identical to the 10mg Prozac capsule. After that, the participant will take a placebo identical to the 20mg Prozac capsule for the duration of the exercise intervention (12 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine Hydrochloride</intervention_name>
    <description>Half of the participants will take fluoxetine for a period of 15-17 weeks (depending on ramp-up period).</description>
    <arm_group_label>Fluoxetine Hydrochloride</arm_group_label>
    <other_name>Prozac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Half of the participants will take the a placebo for a period of 15-17 weeks (depending on ramp-up period).</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>&quot;Sugar&quot; Pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise Program</intervention_name>
    <description>All participants will take part in a 12-week exercise program. The program will run 3 times/week, 1 hour/class.</description>
    <arm_group_label>Fluoxetine Hydrochloride</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  25 years of age or older

          -  Days post stroke must be between 60 - 210 days when enrolled

          -  Measurable hemiparesis at enrollment with a lower limb Fugl-Meyer score &lt; 30

        Exclusion Criteria:

          -  Patients with subarachnoid hemorrhage

          -  Pre-morbid modified Rankin score &gt; 2

          -  Substantial premorbid disability or pre-existing deficit or language comprehension
             deficit that could interfere with assessments

          -  Diagnosis of major depressive disorder/anxiety disorder requiring antidepressant use
             within 6 weeks of enrolment

          -  Taking neuroleptic drugs, benzodiazepines, monoamine oxidase inhibitors within 30 days
             of enrolment

          -  Unstable serious medical condition (e.g., terminal cancer, renal or liver failure,
             congestive heart failure)

          -  Resting blood pressure exceeding 180/100mmHg

          -  Requires more than a one person assist for transfer

          -  Planned surgery that would affect participation in the trial

          -  Participating in another exercise program more than one day per week

          -  Cannot be pregnant

          -  Patients with an ongoing history of illicit drug use and/or alcohol abuse

          -  Patient unwilling or unable to comply with trial requirements

          -  Patient unable to understand English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Bayley, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janice Eng, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia &amp; GF Strong Rehab Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandra Black, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sean Dukelow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William McIlroy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Waterloo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michelle Ploughman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial University of Newfoundland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marilyn Mackay-Lyons, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dalhousie University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Teasell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parkwood Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Farrell Leibovitch, M.Sc</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>7548</phone_ext>
    <email>farrell@canadianstroke.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 1N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Farrell Leibovitch</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>7548</phone_ext>
      <email>farrell@canadianstroke.ca</email>
    </contact>
    <investigator>
      <last_name>Sean Dukelow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia &amp; GF Strong Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 2G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Farrell Leibovitch</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>7548</phone_ext>
      <email>farrell@canadianstroke.ca</email>
    </contact>
    <investigator>
      <last_name>Janice Eng, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial University of Newfoundland</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3X9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Farrell Leibovitch</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>7548</phone_ext>
      <email>farrell@canadianstroke.ca</email>
    </contact>
    <investigator>
      <last_name>Michelle Ploughman, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dalhousie University</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 4R2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Farrell Leibovitch</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>7548</phone_ext>
      <email>farrell@canadianstroke.ca</email>
    </contact>
    <investigator>
      <last_name>Marilyn Mackay-Lyons, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkwood Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 0A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Farrell Leibovitch</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>7548</phone_ext>
      <email>farrell@canadianstroke.ca</email>
    </contact>
    <investigator>
      <last_name>Robert Teasell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Farrell Leibovitch</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>7548</phone_ext>
      <email>farrell@canadianstroke.ca</email>
    </contact>
    <investigator>
      <last_name>Sandra Black, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto Rehabilitation Institute - University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2A2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Farrell Leibovitch</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>7548</phone_ext>
      <email>farrell@canadianstroke.ca</email>
    </contact>
    <investigator>
      <last_name>Mark Bayley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Waterloo</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2L 3G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Farrell Leibovitch</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>7548</phone_ext>
      <email>farrell@canadianstroke.ca</email>
    </contact>
    <investigator>
      <last_name>William McIlroy, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robyn Ibey, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.heartandstroke.ca/articles/research-breakthrough-to-revolutionize-stroke-treatment</url>
    <description>Research breakthrough to revolutionize stroke treatment</description>
  </link>
  <link>
    <url>http://www.phac-aspc.gc.ca/publicat/2009/cvd-avc/pdf/cvd-avs-2009-eng.pdf</url>
    <description>Tracking Heart Disease and Stroke in Canada</description>
  </link>
  <reference>
    <citation>Alexander LD, Black SE, Patterson KK, Gao F, Danells CJ, McIlroy WE. Association between gait asymmetry and brain lesion location in stroke patients. Stroke. 2009 Feb;40(2):537-44. doi: 10.1161/STROKEAHA.108.527374. Epub 2008 Dec 24.</citation>
    <PMID>19109546</PMID>
  </reference>
  <reference>
    <citation>AVERT Trial Collaboration group. Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial. Lancet. 2015 Jul 4;386(9988):46-55. doi: 10.1016/S0140-6736(15)60690-0. Epub 2015 Apr 16. Erratum in: Lancet. 2015 Jul 4;386(9988):30.</citation>
    <PMID>25892679</PMID>
  </reference>
  <reference>
    <citation>Salbach NM, Wood-Dauphinee S, Desrosiers J, Eng JJ, Graham ID, Jaglal SB, Korner-Bitensky N, MacKay-Lyons M, Mayo NE, Richards CL, Teasell RW, Zwarenstein M, Bayley MT; Stroke Canada Optimization of Rehabilitation By Evidence – Implementation Trial (SCORE-IT) Team. Facilitated interprofessional implementation of a physical rehabilitation guideline for stroke in inpatient settings: process evaluation of a cluster randomized trial. Implement Sci. 2017 Aug 1;12(1):100. doi: 10.1186/s13012-017-0631-7.</citation>
    <PMID>28764752</PMID>
  </reference>
  <reference>
    <citation>Bensimon K, Herrmann N, Swardfager W, Yi H, Black SE, Gao FQ, Snaiderman A, Lanctôt KL. Kynurenine and depressive symptoms in a poststroke population. Neuropsychiatr Dis Treat. 2014 Sep 22;10:1827-35. doi: 10.2147/NDT.S65740. eCollection 2014.</citation>
    <PMID>25285006</PMID>
  </reference>
  <reference>
    <citation>Berends HI, Nijlant J, van Putten M, Movig KL, IJzerman MJ. Single dose of fluoxetine increases muscle activation in chronic stroke patients. Clin Neuropharmacol. 2009 Jan-Feb;32(1):1-5.</citation>
    <PMID>19536922</PMID>
  </reference>
  <reference>
    <citation>Biernaskie J, Chernenko G, Corbett D. Efficacy of rehabilitative experience declines with time after focal ischemic brain injury. J Neurosci. 2004 Feb 4;24(5):1245-54.</citation>
    <PMID>14762143</PMID>
  </reference>
  <reference>
    <citation>Billinger SA, Arena R, Bernhardt J, Eng JJ, Franklin BA, Johnson CM, MacKay-Lyons M, Macko RF, Mead GE, Roth EJ, Shaughnessy M, Tang A; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Clinical Cardiology. Physical activity and exercise recommendations for stroke survivors: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 Aug;45(8):2532-53. doi: 10.1161/STR.0000000000000022. Epub 2014 May 20.</citation>
    <PMID>24846875</PMID>
  </reference>
  <reference>
    <citation>Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon SB. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature. 2002 Apr 11;416(6881):636-40.</citation>
    <PMID>11948352</PMID>
  </reference>
  <reference>
    <citation>Breceda EY, Dromerick AW. Motor rehabilitation in stroke and traumatic brain injury: stimulating and intense. Curr Opin Neurol. 2013 Dec;26(6):595-601. doi: 10.1097/WCO.0000000000000024. Review.</citation>
    <PMID>24141528</PMID>
  </reference>
  <reference>
    <citation>Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, Bejot Y, Deltour S, Jaillard A, Niclot P, Guillon B, Moulin T, Marque P, Pariente J, Arnaud C, Loubinoux I. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011 Feb;10(2):123-30. doi: 10.1016/S1474-4422(10)70314-8. Epub 2011 Jan 7. Erratum in: Lancet Neurol. 2011 Mar;10(3):205.</citation>
    <PMID>21216670</PMID>
  </reference>
  <reference>
    <citation>Cumberland Consensus Working Group, Cheeran B, Cohen L, Dobkin B, Ford G, Greenwood R, Howard D, Husain M, Macleod M, Nudo R, Rothwell J, Rudd A, Teo J, Ward N, Wolf S. The future of restorative neurosciences in stroke: driving the translational research pipeline from basic science to rehabilitation of people after stroke. Neurorehabil Neural Repair. 2009 Feb;23(2):97-107. doi: 10.1177/1545968308326636.</citation>
    <PMID>19189939</PMID>
  </reference>
  <reference>
    <citation>Dhami KS, Churchward MA, Baker GB, Todd KG. Fluoxetine and citalopram decrease microglial release of glutamate and D-serine to promote cortical neuronal viability following ischemic insult. Mol Cell Neurosci. 2013 Sep;56:365-74. doi: 10.1016/j.mcn.2013.07.006. Epub 2013 Jul 19.</citation>
    <PMID>23876875</PMID>
  </reference>
  <reference>
    <citation>Dromerick AW, Edwardson MA, Edwards DF, Giannetti ML, Barth J, Brady KP, Chan E, Tan MT, Tamboli I, Chia R, Orquiza M, Padilla RM, Cheema AK, Mapstone ME, Fiandaca MS, Federoff HJ, Newport EL. Critical periods after stroke study: translating animal stroke recovery experiments into a clinical trial. Front Hum Neurosci. 2015 Apr 29;9:231. doi: 10.3389/fnhum.2015.00231. eCollection 2015.</citation>
    <PMID>25972803</PMID>
  </reference>
  <reference>
    <citation>Espinera AR, Ogle ME, Gu X, Wei L. Citalopram enhances neurovascular regeneration and sensorimotor functional recovery after ischemic stroke in mice. Neuroscience. 2013 Sep 5;247:1-11. doi: 10.1016/j.neuroscience.2013.04.011. Epub 2013 Apr 13.</citation>
    <PMID>23590907</PMID>
  </reference>
  <reference>
    <citation>Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, Roy D, Jovin TG, Willinsky RA, Sapkota BL, Dowlatshahi D, Frei DF, Kamal NR, Montanera WJ, Poppe AY, Ryckborst KJ, Silver FL, Shuaib A, Tampieri D, Williams D, Bang OY, Baxter BW, Burns PA, Choe H, Heo JH, Holmstedt CA, Jankowitz B, Kelly M, Linares G, Mandzia JL, Shankar J, Sohn SI, Swartz RH, Barber PA, Coutts SB, Smith EE, Morrish WF, Weill A, Subramaniam S, Mitha AP, Wong JH, Lowerison MW, Sajobi TT, Hill MD; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015 Mar 12;372(11):1019-30. doi: 10.1056/NEJMoa1414905. Epub 2015 Feb 11.</citation>
    <PMID>25671798</PMID>
  </reference>
  <reference>
    <citation>Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, Powers WJ, DeCarli C, Merino JG, Kalaria RN, Vinters HV, Holtzman DM, Rosenberg GA, Wallin A, Dichgans M, Marler JR, Leblanc GG. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006 Sep;37(9):2220-41. Epub 2006 Aug 17. Erratum in: Stroke. 2007 Mar;38(3):1118. Wallin, Anders [added].</citation>
    <PMID>16917086</PMID>
  </reference>
  <reference>
    <citation>Hackett ML, Duncan JR, Anderson CS, Broad JB, Bonita R. Health-related quality of life among long-term survivors of stroke : results from the Auckland Stroke Study, 1991-1992. Stroke. 2000 Feb;31(2):440-7.</citation>
    <PMID>10657420</PMID>
  </reference>
  <reference>
    <citation>Harris JE, Eng JJ, Miller WC, Dawson AS. A self-administered Graded Repetitive Arm Supplementary Program (GRASP) improves arm function during inpatient stroke rehabilitation: a multi-site randomized controlled trial. Stroke. 2009 Jun;40(6):2123-8. doi: 10.1161/STROKEAHA.108.544585. Epub 2009 Apr 9.</citation>
    <PMID>19359633</PMID>
  </reference>
  <reference>
    <citation>Hsieh YW, Wang CH, Sheu CF, Hsueh IP, Hsieh CL. Estimating the minimal clinically important difference of the Stroke Rehabilitation Assessment of Movement measure. Neurorehabil Neural Repair. 2008 Nov-Dec;22(6):723-7. doi: 10.1177/1545968308316385. Epub 2008 Sep 5.</citation>
    <PMID>18776067</PMID>
  </reference>
  <reference>
    <citation>Hsueh IP, Hsu MJ, Sheu CF, Lee S, Hsieh CL, Lin JH. Psychometric comparisons of 2 versions of the Fugl-Meyer Motor Scale and 2 versions of the Stroke Rehabilitation Assessment of Movement. Neurorehabil Neural Repair. 2008 Nov-Dec;22(6):737-44. doi: 10.1177/1545968308315999. Epub 2008 Jul 21.</citation>
    <PMID>18645189</PMID>
  </reference>
  <reference>
    <citation>Iadecola C, Anrather J. Stroke research at a crossroad: asking the brain for directions. Nat Neurosci. 2011 Oct 26;14(11):1363-8. doi: 10.1038/nn.2953.</citation>
    <PMID>22030546</PMID>
  </reference>
  <reference>
    <citation>Jørgensen HS, Nakayama H, Raaschou HO, Vive-Larsen J, Støier M, Olsen TS. Outcome and time course of recovery in stroke. Part I: Outcome. The Copenhagen Stroke Study. Arch Phys Med Rehabil. 1995 May;76(5):399-405.</citation>
    <PMID>7741608</PMID>
  </reference>
  <reference>
    <citation>Kobayashi K, Ikeda Y, Sakai A, Yamasaki N, Haneda E, Miyakawa T, Suzuki H. Reversal of hippocampal neuronal maturation by serotonergic antidepressants. Proc Natl Acad Sci U S A. 2010 May 4;107(18):8434-9. doi: 10.1073/pnas.0912690107. Epub 2010 Apr 19.</citation>
    <PMID>20404165</PMID>
  </reference>
  <reference>
    <citation>Krakauer JW, Carmichael ST, Corbett D, Wittenberg GF. Getting neurorehabilitation right: what can be learned from animal models? Neurorehabil Neural Repair. 2012 Oct;26(8):923-31. doi: 10.1177/1545968312440745. Epub 2012 Mar 30.</citation>
    <PMID>22466792</PMID>
  </reference>
  <reference>
    <citation>Kwah LK, Harvey LA, Diong J, Herbert RD. Models containing age and NIHSS predict recovery of ambulation and upper limb function six months after stroke: an observational study. J Physiother. 2013 Sep;59(3):189-97. doi: 10.1016/S1836-9553(13)70183-8. Erratum in: J Physiother. 2013 Dec;59(4):218.</citation>
    <PMID>23896334</PMID>
  </reference>
  <reference>
    <citation>Langdon KD, Corbett D. Improved working memory following novel combinations of physical and cognitive activity. Neurorehabil Neural Repair. 2012 Jun;26(5):523-32. doi: 10.1177/1545968311425919. Epub 2011 Dec 9.</citation>
    <PMID>22157145</PMID>
  </reference>
  <reference>
    <citation>Levine B, Schweizer TA, O'Connor C, Turner G, Gillingham S, Stuss DT, Manly T, Robertson IH. Rehabilitation of executive functioning in patients with frontal lobe brain damage with goal management training. Front Hum Neurosci. 2011 Feb 17;5:9. doi: 10.3389/fnhum.2011.00009. eCollection 2011.</citation>
    <PMID>21369362</PMID>
  </reference>
  <reference>
    <citation>Lynch E, Hillier S, Cadilhac D. When should physical rehabilitation commence after stroke: a systematic review. Int J Stroke. 2014 Jun;9(4):468-78. doi: 10.1111/ijs.12262. Epub 2014 Mar 18. Review.</citation>
    <PMID>24636633</PMID>
  </reference>
  <reference>
    <citation>Mackay-Lyons M, McDonald A, Matheson J, Eskes G, Klus MA. Dual effects of body-weight supported treadmill training on cardiovascular fitness and walking ability early after stroke: a randomized controlled trial. Neurorehabil Neural Repair. 2013 Sep;27(7):644-53. doi: 10.1177/1545968313484809. Epub 2013 Apr 18.</citation>
    <PMID>23599221</PMID>
  </reference>
  <reference>
    <citation>Mansfield A, Wong JS, Bryce J, Brunton K, Inness EL, Knorr S, Jones S, Taati B, McIlroy WE. Use of Accelerometer-Based Feedback of Walking Activity for Appraising Progress With Walking-Related Goals in Inpatient Stroke Rehabilitation: A Randomized Controlled Trial. Neurorehabil Neural Repair. 2015 Oct;29(9):847-57. doi: 10.1177/1545968314567968. Epub 2015 Jan 20.</citation>
    <PMID>25605632</PMID>
  </reference>
  <reference>
    <citation>Maya Vetencourt JF, Sale A, Viegi A, Baroncelli L, De Pasquale R, O'Leary OF, Castrén E, Maffei L. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science. 2008 Apr 18;320(5874):385-8. doi: 10.1126/science.1150516.</citation>
    <PMID>18420937</PMID>
  </reference>
  <reference>
    <citation>McEwen D, Taillon-Hobson A, Bilodeau M, Sveistrup H, Finestone H. Virtual reality exercise improves mobility after stroke: an inpatient randomized controlled trial. Stroke. 2014 Jun;45(6):1853-5. doi: 10.1161/STROKEAHA.114.005362. Epub 2014 Apr 24.</citation>
    <PMID>24763929</PMID>
  </reference>
  <reference>
    <citation>McIntyre A, Richardson M, Janzen S, Hussein N, Teasell R. The evolution of stroke rehabilitation randomized controlled trials. Int J Stroke. 2014 Aug;9(6):789-92. doi: 10.1111/ijs.12272. Epub 2014 Mar 13.</citation>
    <PMID>24621406</PMID>
  </reference>
  <reference>
    <citation>Murphy TH, Corbett D. Plasticity during stroke recovery: from synapse to behaviour. Nat Rev Neurosci. 2009 Dec;10(12):861-72. doi: 10.1038/nrn2735. Epub 2009 Nov 4. Review.</citation>
    <PMID>19888284</PMID>
  </reference>
  <reference>
    <citation>Nadeau SE, Wu SS, Dobkin BH, Azen SP, Rose DK, Tilson JK, Cen SY, Duncan PW; LEAPS Investigative Team. Effects of task-specific and impairment-based training compared with usual care on functional walking ability after inpatient stroke rehabilitation: LEAPS Trial. Neurorehabil Neural Repair. 2013 May;27(4):370-80. doi: 10.1177/1545968313481284. Epub 2013 Mar 15.</citation>
    <PMID>23504552</PMID>
  </reference>
  <reference>
    <citation>Pizzorusso T, Medini P, Berardi N, Chierzi S, Fawcett JW, Maffei L. Reactivation of ocular dominance plasticity in the adult visual cortex. Science. 2002 Nov 8;298(5596):1248-51.</citation>
    <PMID>12424383</PMID>
  </reference>
  <reference>
    <citation>Ploughman M, Granter-Button S, Chernenko G, Tucker BA, Mearow KM, Corbett D. Endurance exercise regimens induce differential effects on brain-derived neurotrophic factor, synapsin-I and insulin-like growth factor I after focal ischemia. Neuroscience. 2005;136(4):991-1001. Epub 2005 Oct 3.</citation>
    <PMID>16203102</PMID>
  </reference>
  <reference>
    <citation>Ploughman M, Windle V, MacLellan CL, White N, Doré JJ, Corbett D. Brain-derived neurotrophic factor contributes to recovery of skilled reaching after focal ischemia in rats. Stroke. 2009 Apr;40(4):1490-5. doi: 10.1161/STROKEAHA.108.531806. Epub 2009 Jan 22.</citation>
    <PMID>19164786</PMID>
  </reference>
  <reference>
    <citation>Pollock A, St George B, Fenton M, Firkins L. Top 10 research priorities relating to life after stroke--consensus from stroke survivors, caregivers, and health professionals. Int J Stroke. 2014 Apr;9(3):313-20. doi: 10.1111/j.1747-4949.2012.00942.x. Epub 2012 Dec 11.</citation>
    <PMID>23227818</PMID>
  </reference>
  <reference>
    <citation>Portelli R, Lowe D, Irwin P, Pearson M, Rudd AG; Intercollegiate Stroke Working Party. Institutionalization after stroke. Clin Rehabil. 2005 Jan;19(1):97-108.</citation>
    <PMID>15704514</PMID>
  </reference>
  <reference>
    <citation>Savitz SI, Cramer SC, Wechsler L; STEPS 3 Consortium. Stem cells as an emerging paradigm in stroke 3: enhancing the development of clinical trials. Stroke. 2014 Feb;45(2):634-9. doi: 10.1161/STROKEAHA.113.003379. Epub 2013 Dec 24. Review.</citation>
    <PMID>24368562</PMID>
  </reference>
  <reference>
    <citation>Scali M, Begenisic T, Mainardi M, Milanese M, Bonifacino T, Bonanno G, Sale A, Maffei L. Fluoxetine treatment promotes functional recovery in a rat model of cervical spinal cord injury. Sci Rep. 2013;3:2217. doi: 10.1038/srep02217.</citation>
    <PMID>23860568</PMID>
  </reference>
  <reference>
    <citation>Soleman S, Yip PK, Duricki DA, Moon LD. Delayed treatment with chondroitinase ABC promotes sensorimotor recovery and plasticity after stroke in aged rats. Brain. 2012 Apr;135(Pt 4):1210-23. doi: 10.1093/brain/aws027. Epub 2012 Mar 6.</citation>
    <PMID>22396394</PMID>
  </reference>
  <reference>
    <citation>Stinear CM, Byblow WD. Predicting and accelerating motor recovery after stroke. Curr Opin Neurol. 2014 Dec;27(6):624-30. doi: 10.1097/WCO.0000000000000153. Review.</citation>
    <PMID>25364953</PMID>
  </reference>
  <reference>
    <citation>Van Breukelen GJ. ANCOVA versus change from baseline: more power in randomized studies, more bias in nonrandomized studies [corrected]. J Clin Epidemiol. 2006 Sep;59(9):920-5. Epub 2006 Jun 23. Erratum in: J Clin Epidemiol. 2006 Dec;59(12):1334.</citation>
    <PMID>16895814</PMID>
  </reference>
  <reference>
    <citation>Vickers AJ. Analysis of variance is easily misapplied in the analysis of randomized trials: a critique and discussion of alternative statistical approaches. Psychosom Med. 2005 Jul-Aug;67(4):652-5.</citation>
    <PMID>16046383</PMID>
  </reference>
  <reference>
    <citation>Wade DT, Skilbeck CE, Wood VA, Langton Hewer R. Long-term survival after stroke. Age Ageing. 1984 Mar;13(2):76-82.</citation>
    <PMID>6731168</PMID>
  </reference>
  <reference>
    <citation>Wahl AS, Omlor W, Rubio JC, Chen JL, Zheng H, Schröter A, Gullo M, Weinmann O, Kobayashi K, Helmchen F, Ommer B, Schwab ME. Neuronal repair. Asynchronous therapy restores motor control by rewiring of the rat corticospinal tract after stroke. Science. 2014 Jun 13;344(6189):1250-5. doi: 10.1126/science.1253050.</citation>
    <PMID>24926013</PMID>
  </reference>
  <reference>
    <citation>Wang CH, Hsieh CL, Dai MH, Chen CH, Lai YF. Inter-rater reliability and validity of the stroke rehabilitation assessment of movement (stream) instrument. J Rehabil Med. 2002 Jan;34(1):20-4.</citation>
    <PMID>11900258</PMID>
  </reference>
  <reference>
    <citation>Wang D, Fawcett J. The perineuronal net and the control of CNS plasticity. Cell Tissue Res. 2012 Jul;349(1):147-60. doi: 10.1007/s00441-012-1375-y. Epub 2012 Mar 23. Review.</citation>
    <PMID>22437874</PMID>
  </reference>
  <reference>
    <citation>Zittel S, Weiller C, Liepert J. Citalopram improves dexterity in chronic stroke patients. Neurorehabil Neural Repair. 2008 May-Jun;22(3):311-4. doi: 10.1177/1545968307312173. Epub 2008 Jan 24.</citation>
    <PMID>18219053</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2018</study_first_submitted>
  <study_first_submitted_qc>February 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Exercise</keyword>
  <keyword>Fluoxetine</keyword>
  <keyword>Randomized Control Trial</keyword>
  <keyword>Rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
    <mesh_term>Cerebrovascular Disorders</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Brain Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Unused blood samples will be processed and centrally stored in cryovials in a minus 80 degrees freezer for future analyses under the supervision of Study Investigator, Dr. Sandra Black (Sunnybrook, M6 West, 2075 Bayview Avenue, Toronto). The intent is to make the stored frozen cryovials available to all Heart and Stroke Foundation Canadian Partnership of Stroke Recovery (CPSR) investigators to apply for access, but it is currently undecided if other researchers will be allowed to apply for access to the samples. Access will be controlled by a Subcommittee of CPSR Investigators who will review and approve requests and oversee access to the biobank. Stored cryovials will remain at Sunnybrook under the supervision of Dr. Sandra Black for a period of up to 10 years.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

